Why the study?
Does sulfinpyrazone reduce cardiac mortality and sudden death in patients shortly after a documented myocardial infarction?
Population
n=1558 patients, beginning 25 to 35 days after a documented myocardial infarction
Comparison
Sulfinpyrazone 200 mg four times a day vs Placebo
Design
RCT, randomized, double-blind
Follow-up
average of 16 months
Loading...
Supports sulfinpyrazone shortly after MI to lower sudden death; extends RCT evidence for antiplatelet benefit in the high-risk window.
Does sulfinpyrazone reduce cardiac mortality and sudden death in patients shortly after a documented myocardial infarction?
Sulfinpyrazone significantly reduces sudden cardiac death during the high-risk period of 2 to 7 months following an acute myocardial infarction.
A 1980 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: